{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:22:20Z","timestamp":1793110940977,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,31]],"date-time":"2021-12-31T00:00:00Z","timestamp":1640908800000},"content-version":"am","delay-in-days":364,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100002655","name":"Beckman Coulter Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.jcyt.2020.06.005","type":"journal-article","created":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T02:07:01Z","timestamp":1595642821000},"page":"77-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Validation of a flow cytometry-based method to quantify viable lymphocyte subtypes in fresh and cryopreserved hematopoietic cellular products"],"prefix":"10.1016","volume":"23","author":[{"given":"Bechara","family":"Mfarrej","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Gaude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Couquiaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Calmels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Chabannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Lemarie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2020.06.005_bib0001","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40425-017-0239-0","article-title":"The Why, what, and How of the New FACT standards for immune effector cells","volume":"5","author":"Maus","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jcyt.2020.06.005_bib0002","article-title":"FACT standards for immune effector cells, First edition, Immune Effector Cell Task Force","volume":"113","author":"F.f.t.a.o.c. therapy","year":"2017","journal-title":"University of Nebraska Medical Center"},{"key":"10.1016\/j.jcyt.2020.06.005_bib0003","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3389\/fimmu.2016.00504","article-title":"Manufacturing Natural Killer Cells as Medicinal Products","volume":"7","author":"Chabannon","year":"2016","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.jcyt.2020.06.005_bib0004","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1158\/1078-0432.CCR-15-1433","article-title":"Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy","volume":"22","author":"Maus","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.jcyt.2020.06.005_bib0005","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s13238-016-0367-1","article-title":"T-cell receptor-engineered T cells for cancer treatment: current status and future directions","volume":"9","author":"Ping","year":"2018","journal-title":"Protein Cell"},{"issue":"7","key":"10.1016\/j.jcyt.2020.06.005_bib0006","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/intimm\/dxw027","article-title":"The present status and future prospects of peptide-based cancer vaccines","volume":"28","author":"Hirayama","year":"2016","journal-title":"Int Immunol"},{"issue":"5","key":"10.1016\/j.jcyt.2020.06.005_bib0007","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.humimm.2017.12.013","article-title":"Regulatory T cells for Tolerance","volume":"79","author":"Kawai","year":"2018","journal-title":"Hum Immunol"},{"key":"10.1016\/j.jcyt.2020.06.005_bib0008","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.3389\/fimmu.2017.01514","article-title":"Update on Dendritic Cell-Induced Immunological and Clinical Tolerance","volume":"8","author":"Obregon","year":"2017","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.jcyt.2020.06.005_bib0009","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/MOT.0b013e328355a979","article-title":"Regulatory macrophages as therapeutic targets and therapeutic agents in solid organ transplantation","volume":"17","author":"Broichhausen","year":"2012","journal-title":"Curr Opin Organ Transplant"},{"issue":"22","key":"10.1016\/j.jcyt.2020.06.005_bib0010","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1016\/j.febslet.2015.08.048","article-title":"The regulatory role of B cells in autoimmunity, infections and cancer: Perspectives beyond IL10 production","volume":"589","author":"Gorosito Serr\u00e1n","year":"2015","journal-title":"FEBS Lett"},{"issue":"12","key":"10.1016\/j.jcyt.2020.06.005_bib0011","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.it.2016.09.006","article-title":"Dendritic Cells and Cancer Immunity","volume":"37","author":"Gardner","year":"2016","journal-title":"Trends Immunol"},{"issue":"10","key":"10.1016\/j.jcyt.2020.06.005_bib0012","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.4049\/jimmunol.1290017","article-title":"Translational applications of flow cytometry in clinical practice","volume":"188","author":"Jaye","year":"2012","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.jcyt.2020.06.005_bib0013","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s12185-007-0018-7","article-title":"ISHAGE-based single-platform flowcytometric analysis for measurement of absolute viable T cells in fresh or cryopreserved products: CD34\/CD133 selected or CD3\/CD19 depleted stem cells, DLI and purified CD56+CD3- NK cells","volume":"87","author":"Koehl","year":"2008","journal-title":"Int J Hematol"},{"issue":"2","key":"10.1016\/j.jcyt.2020.06.005_bib0014","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/cyto.b.21328","article-title":"Generation and flow cytometric quality control of clinical-scale TCR\u03b1\u03b2\/CD19-depleted grafts","volume":"92","author":"Bremm","year":"2017","journal-title":"Cytometry B Clin Cytom"},{"issue":"11","key":"10.1016\/j.jcyt.2020.06.005_bib0015","first-page":"2213","article-title":"Comparison of Simultaneous CD34+ and CD3+ Quantification with a Modified Stem Cell Enumeration Kit on Two Different Flow Cytometers","volume":"62","author":"Strobel","year":"2016","journal-title":"Clin Lab"},{"issue":"2","key":"10.1016\/j.jcyt.2020.06.005_bib0016","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jim.2010.07.004","article-title":"Recommendations for the validation of flow cytometric testing during drug development: I instrumentation","volume":"363","author":"Green","year":"2011","journal-title":"J Immunol Methods"},{"issue":"2","key":"10.1016\/j.jcyt.2020.06.005_bib0017","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jim.2010.09.036","article-title":"Recommendations for the validation of flow cytometric testing during drug development: II assays","volume":"363","author":"O'Hara","year":"2011","journal-title":"J Immunol Methods"},{"issue":"5","key":"10.1016\/j.jcyt.2020.06.005_bib0018","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/cyto.b.21105","article-title":"Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS\u2014part II\u2014preanalytical issues","volume":"84","author":"Davis","year":"2013","journal-title":"Cytometry B Clin Cytom"},{"issue":"5","key":"10.1016\/j.jcyt.2020.06.005_bib0019","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/cyto.b.21106","article-title":"Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS\u2014part III\u2014analytical issues","volume":"84","author":"Tanqri","year":"2013","journal-title":"Cytometry B Clin Cytom"},{"issue":"5","key":"10.1016\/j.jcyt.2020.06.005_bib0020","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/cyto.b.21107","article-title":"Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS\u2014part IV\u2014postanalytic considerations","volume":"84","author":"Barnett","year":"2013","journal-title":"Cytometry B Clin Cytom"},{"issue":"5","key":"10.1016\/j.jcyt.2020.06.005_bib0021","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/cyto.b.21108","article-title":"Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS\u2014part V\u2014assay performance criteria","volume":"84","author":"Wood","year":"2013","journal-title":"Cytometry B Clin Cytom"},{"issue":"16","key":"10.1016\/j.jcyt.2020.06.005_bib0022","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.4155\/bio-2017-0093","article-title":"Best practices in performing flow cytometry in a regulated environment: feedback from experience within the European Bioanalysis Forum","volume":"9","author":"der Strate","year":"2017","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jcyt.2020.06.005_bib0023","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.clinbiochem.2018.01.017","article-title":"What information on measurement uncertainty should be communicated to clinicians, and how?","volume":"57","author":"Plebani","year":"2018","journal-title":"Clin Biochem"},{"issue":"12","key":"10.1016\/j.jcyt.2020.06.005_bib0024","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1007\/s11095-009-9972-5","article-title":"An approach to the validation of flow cytometry methods","volume":"26","author":"Cunliffe","year":"2009","journal-title":"Pharm Res"},{"issue":"2","key":"10.1016\/j.jcyt.2020.06.005_bib0025","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/cyto.b.21397","article-title":"Validation of Immunomonitoring Methods for Application in Clinical Studies: The HLA-Peptide Multimer Staining Assay","volume":"94","author":"Chandran","year":"2018","journal-title":"Cytometry B Clin Cytom"},{"issue":"4","key":"10.1016\/j.jcyt.2020.06.005_bib0026","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s11899-017-0395-9","article-title":"Considerations in T Cell Therapy Product Development for B Cell Leukemia and Lymphoma Immunotherapy","volume":"12","author":"Fesnak","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"issue":"8","key":"10.1016\/j.jcyt.2020.06.005_bib0027","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s11095-018-2436-z","article-title":"Chimeric Antigen Receptor T-Cells (CAR T-Cells) for Cancer Immunotherapy\u2014Moving Target for Industry?","volume":"35","author":"Salmikangas","year":"2018","journal-title":"Pharm Res"},{"issue":"304","key":"10.1016\/j.jcyt.2020.06.005_bib0028","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1126\/scitranslmed.aaa7721","article-title":"Hurdles in therapy with regulatory T cells","volume":"7","author":"Trzonkowski","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jcyt.2020.06.005_bib0029","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jim.2018.09.012","article-title":"Automated closed-system manufacturing of human monocyte-derived dendritic cells for cancer immunotherapy","volume":"463","author":"Erdmann","year":"2018","journal-title":"J Immunol Methods"},{"issue":"6","key":"10.1016\/j.jcyt.2020.06.005_bib0030","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.bbmt.2013.03.001","article-title":"Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose","volume":"19","author":"Bar","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2020.06.005_bib0031","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3389\/fonc.2013.00118","article-title":"Clinical grade purification and expansion of NK cell products for an optimized manufacturing protocol","volume":"3","author":"Koehl","year":"2013","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.jcyt.2020.06.005_bib0032","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/cgt.2014.78","article-title":"Towards a commercial process for the manufacture of genetically modified T cells for therapy","volume":"22","author":"Kaiser","year":"2015","journal-title":"Cancer Gene Ther"},{"issue":"10","key":"10.1016\/j.jcyt.2020.06.005_bib0033","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1089\/hum.2017.157","article-title":"Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells","volume":"28","author":"Kl\u00f6\u00df","year":"2017","journal-title":"Hum Gene Ther"},{"issue":"10","key":"10.1016\/j.jcyt.2020.06.005_bib0034","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1089\/hum.2017.111","article-title":"Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use","volume":"28","author":"Lock","year":"2017","journal-title":"Hum Gene Ther"},{"issue":"1","key":"10.1016\/j.jcyt.2020.06.005_bib0035","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12967-017-1133-8","article-title":"Generation of donor-specific Tr1 cells to be used after kidney transplantation and definition of the timing of their in vivo infusion in the presence of immunosuppression","volume":"15","author":"Mfarrej","year":"2017","journal-title":"J Transl Med"},{"issue":"7","key":"10.1016\/j.jcyt.2020.06.005_bib0036","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.bbmt.2015.03.012","article-title":"Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?","volume":"21","author":"Radujkovic","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jcyt.2020.06.005_bib0037","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/cyto.b.20370","article-title":"Flow cytometric lymphocyte subset enumeration: 10 years of external quality assessment in the Benelux countries","volume":"74","author":"Levering","year":"2008","journal-title":"Cytometry B Clin Cytom"},{"issue":"2","key":"10.1016\/j.jcyt.2020.06.005_bib0038","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/cyto.b.21531","article-title":"Laboratory Accuracy Improvement in the UK NEQAS Leucocyte Immunophenotyping Immune Monitoring Program: An Eleven-Year Review via Longitudinal Mixed Effects Modeling","volume":"94","author":"Bainbridge","year":"2018","journal-title":"Cytometry B Clin Cytom"},{"issue":"5","key":"10.1016\/j.jcyt.2020.06.005_bib0039","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/trf.14003","article-title":"Autologous lymphapheresis for the production of chimeric antigen receptor T cells","volume":"57","author":"Allen","year":"2017","journal-title":"Transfusion"},{"issue":"5","key":"10.1016\/j.jcyt.2020.06.005_bib0040","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/cyto.b.21751","article-title":"(AFC-AG), Acceptable \u201cReal-Life\u201d Variability for Lymphocyte Counts by Flow Cytometry","volume":"96","author":"Ticchioni","year":"2019","journal-title":"Cytometry B Clin Cytom"},{"issue":"1","key":"10.1016\/j.jcyt.2020.06.005_bib0041","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s12967-017-1330-5","article-title":"GMP-production of purified human B lymphocytes for the adoptive transfer in patients after allogeneic hematopoietic stem cell transplantation","volume":"15","author":"Tittlbach","year":"2017","journal-title":"J Transl Med"},{"key":"10.1016\/j.jcyt.2020.06.005_bib0042","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.omtm.2018.01.006","article-title":"A Rapamycin-Based GMP-Compatible Process for the Isolation and Expansion of Regulatory T Cells for Clinical Trials","volume":"8","author":"Fraser","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"3","key":"10.1016\/j.jcyt.2020.06.005_bib0043","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jcyt.2018.11.009","article-title":"Manufacturing chimeric antigen receptor T cells: issues and challenges","volume":"21","author":"Roddie","year":"2019","journal-title":"Cytotherapy"},{"issue":"8","key":"10.1016\/j.jcyt.2020.06.005_bib0044","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.3390\/ijms17081316","article-title":"Development of a Modular Assay for Detailed Immunophenotyping of Peripheral Human Whole Blood Samples by Multicolor Flow Cytometry","volume":"17","author":"R\u00fchle","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.jcyt.2020.06.005_bib0045","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/2047-1440-2-17","article-title":"Standardization of whole blood immune phenotype monitoring for clinical trials: panels and methods from the ONE study","volume":"2","author":"Streitz","year":"2013","journal-title":"Transplant Res"},{"issue":"2","key":"10.1016\/j.jcyt.2020.06.005_bib0046","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3390\/biomedicines5020033","article-title":"T-Cell Manipulation Strategies to Prevent Graft-Versus-Host Disease in Haploidentical Stem Cell Transplantation","volume":"5","author":"Vadakekolathu","year":"2017","journal-title":"Biomedicines"},{"key":"10.1016\/j.jcyt.2020.06.005_bib0047","doi-asserted-by":"crossref","first-page":"43873","DOI":"10.1038\/srep43873","article-title":"Standardized and flexible eight colour flow cytometry panels harmonized between different laboratories to study human NK cell phenotype and function","volume":"7","author":"Veluchamy","year":"2017","journal-title":"Sci Rep"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324920307817?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324920307817?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T01:42:34Z","timestamp":1761442954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324920307817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S1465324920307817"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2020.06.005","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Validation of a flow cytometry-based method to quantify viable lymphocyte subtypes in fresh and cryopreserved hematopoietic cellular products","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2020.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}